The purpose of this study was to characterize mitoxantronetreated with chemotherapy alone remains low. In first-line induced cytotoxicity in KG1a and TF-1, two P-glycoprotein therapy, the 'gold standard' induction regimen consists of the expressing AML cell lines which display early differentiation administration of the anthracycline daunorubicin (DNR) in phenotypes, compared to more mature HL-60 and U937 cells.
than DNR towards immature AML cells.
Mitoxantrone, an anthracenedione derivative, is a potent antitumor agent with proven activity against a number of Introduction human neoplasias, including AML. [10] [11] [12] The cytotoxic action Acute myeloid leukemia (AML) is a neoplastic disorder of mitoxantrone is believed to be associated with its ability to characterized by the clonal expansion of leukemic myeloid stabilize a covalent DNA-topoisomerase II reaction product, cells. In spite of apparent uniformity, AML cells consist of a the so-called cleavable complex (for review see Ref. 10 ). More heterogeneous cellular population. A small fraction of leurecently, it has been demonstrated that mitoxantrone induces kemic progenitor cells (CFU-L) proliferate and differentiate programmed cell death (apoptosis) in certain leukemia cells 13 into terminal division blast cells which comprise the vast although it remains unclear whether mitoxantrone-induced majority of leukemic cells observed in the blood and marrow apoptosis is a direct consequence of the mitoxantrone-topoof AML patients. 1 Similar to normal hemopoiesis, the leuisomerase II interaction. kemic myeloid progenitor compartment appears to be heteroTo the best of our knowledge, no study has been performed geneous with the less mature progenitors providing the selfevaluating the cytotoxic effects of mitoxantrone on AML cells renewal activity of the AML clone. 2 The phenotypic identifiderived from distinct stages of differentiation. Therefore, we cation of the most primitive AML cells has been lacking until have evaluated drug transport, drug-topoisomerase II interacrecent studies showed that leukemia initiating cells (SL-IC) tions, and cytotoxicity of mitoxantrone in two AML cell lines which can engraft SCID mice, and which can therefore be which express the early differentiation phenotype (KG1a and considered as leukemic stem cells, display the early CD34 + TF-1) compared to two AML cell lines which display a more CD33 − CD38 − phenotype. 3 Thus, the elimination of this early mature phenotype (HL-60 and U937). Our results show that AML cell subpopulation by chemotherapy is probably the the CD34 + cell lines display natural resistance to mitoxantrone most critical step to eradicate the AML. 1 independent of drug transport and drug-target interaction. The Despite many efforts, the survival rate of AML patients resistance is associated with the ability to block cell cycle progression in the G2 phase and with the absence of apoptosis. for HL-60 and U937. P-gp was detected in KG1a and TF-1 Tris-HCl, pH 8, 20 mM EDTA, 0.5% Triton X-100) for 30 min. DNA fragments were separated by centrifugation (20 000 g for but not in HL-60 and U937. Furthermore, KG1a cells exhibited much higher P-gp efflux capacity than TF-1 cells. 8 30 min) and the radioactivity in the pellet (intact DNA) and supernatant (degraded ADN) was determined by liquid scintillation counting.
DNA internucleosomal fragmentation was also charac-MTT cytotoxicity assay terized by conventional agarose gel electrophoresis as previously described. 18 Briefly, cells (2 × 10 6 ) were lysed in Exponentially grown AML cells (5 × 10 5 cells/ml) were incubated with or without mitoxantrone for 6 h at 37°C. Cells were 10 mM Tris-HCl, 10 mM EDTA, 10 mM NaCl, 0.5% SDS, pH 7.4 and 0.5 mg/ml proteinase K and incubated 1 h at then washed and resuspended at 2 × 10 5 cells/ml, and 0.1 ml aliquots were removed and seeded in 96-well plates for an 50°C. The mixture was then treated with RNAse A (200 g/ml) at 50°C for 2 h. DNA was precipitated by ethanol and separadditional 48 h incubation in drug-free medium. Growth inhibition was quantitated with a thermoMax microplate reader ated by electrophoresis in 1.8% agarose gel. DNA was visualized by ethidium bromide and photographed under UV according to Mossman. 14 The IC 50 (drug concentration resulting in 50% inhibition of MTT dye formation, compared illumination. Pulse-field gel electrophoresis was conducted according to to controls) was determined directly from semi-logarithmic dose-response curves.
a previously published method. 19 Briefly, 4 × 10 6 cells were embedded in 0.7% low-melting agarose (Sea Plaque Agarose; FMC Bioproducts, Rockland, ME, USA). Agarose plugs were incubated overnight at 50°C in lysis buffer Mitoxantrone accumulation (pH 9.5), 10 mM NaCl, 25 mM EDTA, 1% sodium sarcosinate) containing 0.2 mg/ml proteinase K. Plugs were then washed Mitoxantrone was added to cells (5 × 10 5 /ml) at 1 or 5 M and incubated at 37°C for various times and harvested. After washthree times for 1 h in TE buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA) and stored in 4 mM EDTA at 4°C prior to analysis. ing at 4°C, the cell pellets (5 × 10 5 ) were resuspended in 200 l phosphate-buffered saline and mitoxantrone fluorSamples, including a 50-1000 kilobase pairs lambda DNA standard (Promega, Madison, WI, USA), were analyzed on a escence was measured by a Becton Dickinson FACScan flow cytometer (San José, CA, USA) with excitation and emission 1% agarose gel (SeaKem FastLane) using a CHEF-DRII pulsedfield electrophoresis system (BioRad Laboratories, Richmond, wavelengths at 488 nm and 63 nm, respectively. The accumulation of mitoxantrone was expressed in arbitrary units by cal-CA, USA) at 200 V with pulse ramping times from 16 to 60 s in a 0.5 × TBE buffer (45 mM Tris-borate, 1 mM EDTA, pH 8). culating the mean fluorescence at different incubation times.
The buffer was recirculated continuously and the temperature maintained at 14°C throughout electrophoresis. The gels were stained with ethidium bromide (0.5 g/ml) and photographed
Measurement of DNA-protein complexes
under UV illumination.
To analyze changes in cell morphology, cells were cytocenThe appearance and removal of DNA-protein complexes was assessed as already described. 15, 16 Briefly, 4 × 10 5 cells/ml trifuged on a microscope slide, fixed in methanol and then stained with Giemsa solution. were incubated with 0.2 Ci/ml 14 C-leucine and 0.6 Ci/ml Nuclear extracts were prepared as previously described. 21 Electrophoretic mobility shift assays were performed by incubMitoxantrone-induced DNA-protein complexes ating 4 g of nuclear extract with 50 000 c.p.m. of 32 P-end labeled NF-B (5′AGTTGAGGGGCTTTCCCAGGC-3′) or AP-1 (5′-CGCTTGATGAGTCAGCCGGAA-3′) consensus oligonu-
The formation of mitoxantrone-stabilized covalent DNA-procleotides in a reaction buffer (2 mM HEPES (pH 7.5), 50 mM tein complexes was measured after 1 h drug exposure. As NaCl, 0.5 mM EDTA, 1 mM MgCl 2 , 4% glycerol, 0.5 mM DTT, 1 g poly (dI-dC), and 2 g BSA). After 20-min incubation, the DNA-protein complex formed was separated from free oligonucleotide by electrophoresis through a low ionic strength 4% native polyacrylamide gel. Electrophoresis was carried out in buffer containing 6.7 mM Tris-HCl (pH 7.9), 3.3 mM sodium acetate, 2 mM EDTA at 10 V/cm for 3 h at room temperature with buffer recirculation. The gel was dried and autoradiographed with intensifying screens at −70°C.
Results

Cytotoxic effect of mitoxantrone
HL-60, U937, KG1a, and TF-1 cells were treated with different doses of mitoxantrone (0.001-5 M). According to the MTT assay, the IC 50 s were 20, 30, 700, and 800 nM for U937, HL-60, KG1a, and TF-1, respectively (Figure 1 ). In the presence of 1 M PSC833, a P-glycoprotein blocker, the chemosensitivity profiles of U937, HL-60, and TF-1 were unaffected whereas the cytotoxic effect towards KG1a cells was increased less than two-fold (data not shown). 
Mitoxantrone-induced DNA fragmentation
Quantitative evaluation of DNA fragmentation was performed with the 3 H-thymidine release assay after short (1 h) or prolonged (6 h) mitoxantrone exposure. In both cases, DNA fragmentation was measured 6 h after drug exposure. After 1 h treatment, mitoxantrone induced a dose-dependent DNA fragmentation in U937 and HL-60 cells within a dose range of 0.1 M to 5 M. In these cells as much as 42 and 73% of the DNA was fragmented for U937 and HL-60, respectively (Figure 5a ). In KG1a and TF-1, mitoxantrone induced less than 10% DNA fragmentation at concentrations up to 1 M whereas 5 M mitoxantrone induced 15% DNA fragmentation (Figure 5b) . Moreover, DNA fragmentation remained unchanged whether the cells were treated with mitoxantrone alone or in combination with PSC833 (data not shown). DNA fragmentation was also measured after 6-h exposure to mitox- shown in Figure 3 , the appearance of these complexes was dose-dependent with a plateau reached at 5 M. Although differences in the amount of DNA-protein complex formation were observed between the four cell lines, none correlated with cytotoxicity. For example, at 5 M the level of DNAprotein complexes was similar in KG1a, TF-1, and HL-60 and slightly decreased in U937. When cells were treated with 1 M mitoxantrone for 6 h, the amount of DNA-protein complexes was maximal at 1 h and remained constant for 6 h. Again no major differences were found between the four cell lines (data not shown). The reversibility of mitoxantroneinduced DNA-protein complexes was evaluated after 1 h exposure to 5 M mitoxantrone. As shown in Figure 4 , the kinetics of DNA-protein complex disappearance was similar for U937 and HL-60 whereas the amount of DNA-protein complexes in KG1a and TF-1 remained stable up to 6 h.
Figure 5
Dose-effect of mitoxantrone on DNA fragmentation in HL-60, U937 (a), KG1a and TF-1 (b). Cell lines were treated with various doses of mitoxantrone for 1 h, washed, resuspended in drugfree medium for an additional 6 h and DNA fragmentation was quantified by the thymidine release assay as described in Materials and ( ), and TF-1 (s).
antrone at doses between 1 and 10 M. Under these conditions, DNA fragmentation peaked at 1 M, decreased at 5 M, and was no longer detectable at 10 M for U937 and HL-60 cells. In KG1a and TF-1 cells, DNA fragmentation remained below 10% of the total DNA whatever the dose used (data not shown).
DNA (Figure 6 ).
The integrity of DNA from HL-60 and KG1a cells was also analyzed by pulse-field gel electrophoresis following treatment with mitoxantrone at 1 and 5 M and post-incubation for different times in drug-free medium. As shown in Figure 7 , exposure of HL-60 to 5 M mitoxantrone resulted in the formation of large DNA fragments with a progressive release of 50 kbp DNA fragments. These fragments were no longer detectable after 4 h of post-incubation. At this time, we observed internucleosomal DNA fragmentation in HL-60 cells treated with the same dose of the drug. In KG1a cells, there was no change in DNA integrity up to 6 h after drug treatment
Figure 7
Pulse-field electrophoresis analysis of DNA fragmentation in HL-60 and KG1a cells treated with 5 M mitoxantrone for 1 h and post-incubated in drug-free medium for 0, 0.5, 1, 2, 4 and 6 h (lanes 1-6). Lane M: 50 kbp DNA ladder.
( Figure 7 ). Similar results were obtained for lower (1 M) dose of mitoxantrone (data not shown). However, for both cell lines we observed the formation of a large unresolved band Ͼ1000 kbp which was not detected in DNA isolated from untreated cells (not shown). This band may correspond to the stabilization of topoisomerase II-DNA cleavable complexes by mitoxantrone.
Morphological studies
The morphology of each cell line 6 h after exposure to 1 M mitoxantrone for 1 h was characterized by light microscopy following Giemsa staining. Sensitive cells displayed typical apoptotic features in up to 90% of the cells whereas less than 10% of the resistant cells showed apoptotic morphology (data not shown). Similar results were observed when cells were treated with 5 M mitoxantrone. After more than 6 h postincubation, a gradual loss of viability was observed for KG1a and TF-1 cells which displayed loss of membrane integrity as assessed by trypan blue with no characteristic features of apoptosis.
Viability assays
The number of viable HL-60 and KG1a cells was determined mitoxantrone was much slower since 50% of KG1a cells were
Discussion
This study was designed to characterize the cytotoxic effects of mitoxantrone toward four different AML cell lines. The results show that KG1a and TF-1 are much more resistant to the drug than HL-60 and U937 indicating that some AML cell populations may display high levels of inherent resistance to mitoxantrone. Since mitoxantrone has recently emerged as a possible alternative to DNR in AML therapy, we felt that it would be important to characterize the mechanisms which underlie the natural resistance of these AML cells to mitoxantrone.
Mitoxantrone is an anticancer anthracenedione drug which is structurally related to the anthracycline antibiotics. Mitoxantrone binds extensively to nucleic acids by intercalation 24 and this binding may explain the ability of mitoxantrone to cause condensation and compaction of chromatin, 25 dissociation of DNA-bound proteins 26 as well as inhibition of DNA, RNA, and protein synthesis. 10 Although it has been proposed that mitoxantrone-induced DNA lesions may also arise age arising from this interaction may explain the observed long-term inhibition of DNA synthesis, cell arrest in the G 2 phase of the cell cycle, and subsequent cell death.
30
Resistance to mitoxantrone has been extensively studied over the last few years. From these studies, it has emerged still viable after 72 h post-treatment and viable cells could be that, in contrast to anthracyclines, resistance to mitoxantrone detected up to 8 days. Moreover, prolonged incubation (3 is generally not mediated through drug-transport abnormaliweeks) in drug-free medium of cells treated with 1 M mitoxties. For example, selection with mitoxantrone induced no antrone resulted in the survival of a small fraction of proliferatdetectable modification of mitoxantrone accumulation and ing KG1a cells (data not shown).
conferred cross-resistance to VP-16, VM-26, and anthracyclines through a non-P-gp mediated mechanism. 31,32 Furthermore, using a large panel of MDR cell lines, it has been shown Cell cycle analysis that vincristine-and doxorubicin-selected cell lines are rarely cross-resistant to mitoxantrone. 9 It seems unlikely that the The effect of mitoxantrone on cell cycle distribution and DNA resistance to mitoxantrone observed for KG1a and TF-1 cells integrity in HL-60 and KG1a after 1 h drug exposure at 1 and could be related to P-gp since the accumulation of mitoxan-5 M over a period of 6 h was analyzed. When HL-60 cells trone was similar for all four cell lines. Furthermore, PSC833, were treated with 5 M mitoxantrone, flow cytometric analysis a potent P-gp blocker, did not influence mitoxantrone revealed that as early as 4 h after treatment, a sub-G 1 subpopaccumulation. These results strongly suggest that the high ulation appeared which can be considered as apoptotic cells.
level of resistance to mitoxantrone displayed by KG1a and This fraction was very prominent after 6 h ( Figure 9 ). Similar TF-1 cells is not related to drug transport. findings were found after treatment with 1 M mitoxantrone A quantitative and/or qualitative modification of topoiso-(data not shown). In contrast, KG1a cells treated with 5 M merase II may severely limit mitoxantrone cytotoxicity as has mitoxantrone displayed a marked arrest in the G 2 -M phase of been described for so-called 'atypical multidrug resistance' the cell cycle at 6 h with no apoptotic peak in the sub-G 1 (at-MDR). 33 In contrast to 'classical MDR', at-MDR is defined region (Figure 9 ); this G 2 -M block persisted for 48 h before the by the lack of P-glycoprotein (P-gp) overexpression, unmodicells started to die (data not shown).
fied drug accumulation, and altered topoisomerase II (for review, see Ref. 34). Our results strongly argue against the implication of at-MDR in the mitoxantrone-resistance of KG1a
Effect of mitoxantrone on NF-B and AP1 activation and TF-1 since we were unable to detect any significant differences in drug-induced DNA-protein complex formation between sensitive and resistant cell lines. It could also be that Since both NF-B and AP1 transcription factors have been involved in the cellular response to DNA damaging drug-induced DNA-protein complexes were more rapidly removed in resistant cells than in sensitive cells as previously agents, 22, 23 we examined whether mitoxantrone (1 M) could activate these transcription factors in KG1a and U937 cells.
reported for VP-16-resistant AML cell lines. 35 This hypothesis also seems unlikely since DNA-protein complexes were As shown in Figure 10 , electrophoretic mobility shift assay showed that mitoxantrone activated NF-B and AP1 in a timeremoved more rapidly in U937 and HL-60 cells than in KG1a and TF-1 cells. However, the apparent disappearance of dependent manner in both cell lines. However, mitoxantroneinduced AP-1 activation was more pronounced in KG1a cells cleavable complexes in sensitive U937 and HL-60 cells may actually be a result of a rapidly occurring apoptotic process. than in U937 cells.
Figure 9
Cell cycle analysis after mitoxantrone exposure of HL-60 and KG1a cells. Cells were treated with 5 M mitoxantrone for 1 h, washed and resuspended in drug-free medium. Cell cycle distribution was analyzed as described in Materials and methods immediately after treatment (T0) or after 6 h.
Altogether, these results suggest that mitoxantrone resistance dose therapy, respectively. 36 In HL-60 and U937 cells, appearance of apoptotic features was associated with a rapid displayed by the KG1a and TF-1 cells is not due to an altered drug-topoisomerase II interaction. Therefore, the decreased decrease in cell viability. More importantly, the kinetics of cell death was similar whether the cells were treated with 1 or mitoxantrone cytotoxicity may be due to modifications of molecular events which take place downstream of the drug-5 M mitoxantrone, suggesting that, in sensitive cells, increasing the dose above a certain threshold concentration may not target interaction.
The cell death process in the different cell lines treated with significantly improve the drug-induced cytotoxic effect. Interestingly, prolonged exposure to high-dose mitoxantrone (5 various doses of mitoxantrone was investigated. In the sensitive HL-60 and U937 cells, 1-h exposure to mitoxantroneand 10 M) over a period of 6 h led to a significant decrease of DNA fragmentation. However, since it has been shown that induced DNA oligonucleosomal fragmentation as well as morphological features of apoptosis at doses ranging between mitoxantrone can condense nucleic acids in solution, 25 it is possible that the drug changes chromatin structure in vivo and 0.1 and 10 M (0.04-4 mg/l). In comparison, bolus injection of mitoxantrone in patients results in AUC (plasma area under impairs the accessibility of endonucleases to their cleavage sites when cells are treated with high doses of mitoxantrone the curve) of 0.90 and 3.5 mg/l/h for conventional and high-
Figure 10
Effect of mitoxantrone on NF-B and AP-1 activation. U937 and KG1a cells were incubated with mitoxantrone for various times at 37°C. Nuclear extracts were isolated and EMSAs were performed as described in Materials and methods. for a prolonged time period. Collectively, these results show p53 gene as previously reported, 39 suggesting that p53 is not required for mitoxantrone-induced apoptosis. Alternatively, it that sensitive cells rapidly die by classical apoptosis and that this cell death pathway can be triggered at drug concenwas conceivable that the inability of the drug to induce apoptosis in KG1a and TF-1 cells could be due to abnormal trations which are clinically relevant.
Mitoxantrone induced much lower DNA fragmentation in regulation of transcription factors such as NF-B 22 and AP-1, 23 which have recently emerged as possible regulators of resistant KG1a and TF-1 cells than it did in sensitive cells. For example, when KG1a and TF-1 cells were treated with cliniapoptosis. The results show that mitoxantrone activated both NF-B and AP-1 as evaluated by EMSA, a result which has cally relevant concentrations of the drug (ie 0.1-1 M) no DNA fragmentation was observed by 6 h. One could specunever been reported before. Although NF-B activation was found to be similar in the mitoxatrone-sensitive U937 cells late that apoptosis was simply delayed in the resistant cells and would have become detectable after a longer observation compared to the mitoxantrone-resistant KG1a cells, AP-1 activation was more pronounced in the latter. Whether or not APperiod. However, no DNA fragmentation was observed during a 96-h post-treatment period during which the cells progress-1 overactivation may be involved in the protection of KG1a cells toward mitoxantrone remains to be investigated. Finally, ively died without apoptotic features. During this period, cell cycle analysis revealed a persistent G 2 -M block as previously it should be pointed out that KG1a and TF-1-resistant myeloid cell lines display an immature phenotype whereas the two reported for other topoisomerase II inhibitors including teniposide and m-AMSA. 37 Altogether, these results suggest that sensitive HL-60 and U937 cell lines exhibit a more mature phenotype. In two recent studies we have reported that other mitoxantrone is unable to induce apoptosis in some AML cells, and that the absence of apoptosis plays an important cytotoxic agents such as daunorubicin 17 and TNF␣ 40 were also unable to induce apoptosis in immature AML cells. role in the natural drug resistance of these cells to mitoxantrone.
Therefore, it is possible that the repression of the apoptotic program is a common feature of immature myeloid leukemia The lack of an apoptotic response of KG1a and TF-1 cells to mitoxantrone could be due to abnormal expression of proteins cells which offers a potential survival advantage to these cells compared to the more mature leukemia hemopoietic involved in the regulation of apoptosis such as Bcl-2 or p53. However, no obvious correlation between the apoptotic compartment.
In conclusion, our study provides evidence that AML cells response to mitoxantrone and Bcl-2 expression was found for the four cell lines, as assessed by Western blot and flow cytodisplay natural resistance to mitoxantrone independently of abnormalities in drug transport or drug-target interactions. In metry analysis (data not shown). Furthermore, although Bcl-2 has been shown to protect tumor cells against a variety of these cells, the resistance mechanism appears to be related to the absence of drug-induced apoptosis. Therefore, the characcytotoxic agents including other topoisomerase II poisons, 38 the role of this protein in mitoxantrone-induced apoptosis terization of the molecular mechanism which acts as a negative regulator of apoptosis in the resistant cells may lead to remains to be elucidated. As far as p53 is concerned, it should be noted that the four cell lines exhibit either mutated or no identification of new chemosensitizers which could restore
